What it is
Retatrutide, also identified as LY3437943, is an agonist at GIP, GLP-1, and glucagon receptors. Its three-target design makes it different from the dual-receptor compound tirzepatide. The cited publication describes a phase 2 obesity trial, not an approval decision. For current regulatory status, consult an up-to-date regulator record; this profile does not establish approval status.[4]
Research areas and evidence
The 2023 double-blind trial enrolled 338 adults with obesity or overweight plus a weight-related condition. It compared retatrutide groups with placebo, using body-weight change at 24 weeks as the primary endpoint and additional outcomes through 48 weeks. Greater average weight reduction was reported in the active groups. These are human findings, not merely animal results, but a phase 2 trial of this size does not establish comparative superiority, all long-term outcomes, or effects in every clinical population.[4]
Safety and unknowns
The most frequent adverse events were gastrointestinal and were related to the study's treatment levels. The investigators also reported increases in heart rate that peaked during the study and later declined. These safety signals are important when interpreting the reported weight changes. The trial was funded by Eli Lilly. Its published results cannot establish the identity, purity, safety, or suitability of material marketed outside that research setting; no purchasing or administration guidance is provided here.[4]
Sources
Read the original studies and reviews. These selected sources may not include newer research.
- Phase 2 randomized human trial[4] Jastreboff et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. NEJM (2023).